Prestige BioPharma Limited (950210.KS) KSC

Currency In KRW

AD

Valuation

Market Cap883.41B
Enterprise Value912.21B
P/E Ratio-6.69
PEG Ratio0.02
Price/Sales Ratio23.72
Price/Book Ratio0.8
Enterprise/Revenue25.11
Enterprise/EBITDA-9.27

Fiscal Year

Fiscal YearJune 30, 2025
Most Recent QuarterMarch 31, 2026

Profitability

Profit Margin-3.55
Operating Margin-5.22
AD

Management Effectiveness

Return On Assets-0.07
Return On Equity-0.14

Income Statement

Revenue14.31B
Revenue/Share269.85
Gross Profit-24.01B
EBITDA33.31B
Net Income22.27B
Diluted EPS370.61

Balance Sheet

Total Cash65.89B
Total Cash/Share1,096.48
Total Debt85.94B
Total Debt/Equity0.18
Current Ratio0.85
Book Value Per Share9,341.16

Price History

52-Week Change-54.48
52-Week High15,900
52-Week Low4,945
Moving Average 50 Days6,282.4
Moving Average 200 Days10,003.4

Statistics

Average Volume85,719
Shares Outstanding60.1M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A
AD